Kadcyla (trastuzumab emtansine)160mg

Kadcyla 160mg contains trastuzumab emtansine, an antibody-drug conjugate that combines trastuzumab with a chemotherapy component. It targets HER2 receptors on cancer cells and delivers the cytotoxic component to these cells. Key Information

• Active Ingredient: Trastuzumab emtansine
• Strength: 160mg
• Uses: Used for certain cases of HER2-positive metastatic and early breast cancer.
• Administration: Administered by intravenous infusion under medical supervision.
• Common Side Effects: Fatigue, nausea, constipation, headache, muscle or joint pain, low platelet counts and peripheral neuropathy may occur.
• Important: Kadcyla can cause serious liver and heart problems and requires appropriate medical monitoring during treatment.

Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice. Consult a qualified healthcare professional before starting or changing any medication.